Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients


Oshadi Drug Administration

Status and phase

Phase 2


Lymphoid Leukemia
Acute Myeloid Leukemia


Drug: Oshadi D & Oshadi R;
Drug: salvage therapy cytosar and mitoxantrone

Study type


Funder types



OS-AM-P2-01 Version 0.1

Details and patient eligibility


The study will be a prospective open-label single-center study in previously treated patients with Acute Myeloid Leukemia (AML) or Acute Lymphoid Leukemia (ALL). Treatment efficacy and safety of the combination of Oshadi D (DNase in Oshadi carrier) and Oshadi R (RNase in Oshadi carrier) with Salvage Chemotherapy will be evaluated. Oshadi D and Oshadi R were shown to have anti-tumor activity and good safety profile. Patients will receive Oshadi D and Oshadi R oral treatment combined with salvage chemotherapy. Patient will be evaluated throughout the study for safety and tolerance to multiple dose regimens of Oshadi D and Oshadi R. Efficacy will be determined by percentage of bone marrow blasts assessment at day 28 post therapy initiation.


15 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Patients is diagnosed as AML or ALL
  • Relapse defined as the presence of disease after the achievement of complete remission(CR). Refractory disease is defined as progression from or no response while treated with a previous line chemotherapy regimen, or progression within 30 days of last bone marrow assessment.
  • Male or female ≥ 18 years of age
  • Minimal performance status (ECOG 0, ≤2)
  • Patients must have a measurable disease by bone marrow blast counts of > 5 % of nucleated cells.
  • Written informed consent
  • Adequate hepatic function (LFTs up to X4 the normal limits), renal function calculated Creatinine clearance (CrCl) for Adverse Effects of >30)
  • Ability to swallow the medications.
  • Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after treatment discontinuation.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.

Exclusion criteria

  • Active infectious disease uncontrolled by antibiotics.
  • Partially treated induction patients (i.e. day 14 non responding patients).
  • Inability to receive high dose salvage chemotherapy.
  • Patient with known positive HIV serology at screening.
  • Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
  • Evidence of ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria for Adverse Effects (CTCAE ) Version 3.0 grade 2.
  • Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
  • Mental disorders.
  • Inability to give written informed consent.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

15 participants in 1 patient group

'Oshadi D & Oshadi R; salvage therapy'
Experimental group
Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
Drug: salvage therapy cytosar and mitoxantrone
Drug: Oshadi D & Oshadi R;

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems